Patients with psoriasis who show an early response to the biologics risankizumab or guselkumab are more likely to have a long ...

Professor Omar Usmani and Respiratory Effectiveness Group colleagues outline a pragmatic approach to inhaler choice and ...

A new study highlights the risks of atopic dermatitis flare-ups after discontinuing dupilumab and the likelihood of restarting treatment.

RPath president Dr Bernie Croal discusses the evolving landscape of pathology in the UK, the challenges and opportunities, and what's next.